CRGX Profile
CARGO Therapeutics, Inc., a clinical-stage biotechnology firm, is focused on the development of innovative chimeric antigen receptor (CAR) T-cell therapies aimed at treating various cancers. The company's lead product candidate, CRG-022, is an autologous CD22 CAR T-cell therapy designed to overcome resistance mechanisms in B-cell malignancies by targeting the CD22 antigen, which is prevalent in these cancers.
In addition to CRG-022, CARGO Therapeutics is advancing CRG-023, a tri-specific CAR T-cell therapy that targets tumor cells expressing three distinct B-cell antigens. This approach is intended to enhance the therapeutic efficacy by addressing multiple antigenic targets on the tumor cells simultaneously, thereby potentially improving treatment outcomes for patients with complex and resistant cancers.
The company's development strategy leverages cutting-edge CAR T-cell technology to create therapies that can provide more effective treatment options for patients with hematologic malignancies and other challenging cancer types. CARGO Therapeutics' research and development efforts are aimed at addressing significant unmet medical needs and advancing the field of cellular immunotherapy.
Established in 2019 and based in San Mateo, California, CARGO Therapeutics was formerly known as Syncopation Life Sciences, Inc. It rebranded to CARGO Therapeutics in September 2022 to better reflect its focus on CAR T-cell therapies. The company's commitment to innovation in cancer treatment continues to drive its clinical and research activities.
|
